Skip to search formSkip to main contentSkip to account menu

cobicistat

Known as: 1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2S)-2-({[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)carbamoyl}amino)-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate, 2,7,10,12-Tetraazatridecanoic acid, 12-methyl-13-(2-(1-methylethyl)-4-thiazolyl)-9-(2-(4-morpholinyl)ethyl)-8,11-dioxo-3,6-bis(phenylmethyl)-, 5-thiazolylmethyl ester, (3R,6R,9S)-, Cobicistat [Chemical/Ingredient] 
A carbamate and thiazole derivative that functions as a CYTOCHROME P450 CYP3A INHIBITOR to enhance the concentration of ANTI-HIV AGENTS, with which… 
National Institutes of Health

Related topics

Related topics

16 relations

Broader (2)

Anti-HIV AgentsCytochrome P-450 CYP3A Inhibitors
Atazanavir / cobicistatBreast Cancer Resistance Protein Inhibitors [MoA]In Bloodagonists

Narrower (5)

EvotazGS 9350GenvoyaPrezcobix

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
In vitro inhibition of human UGT isoforms by ritonavir and cobicistat
Abstract 1. Ritonavir and cobicistat are pharmacokinetic boosting agents used to increase systemic exposure to other… 
2017
2017
Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF
Background: The dose of tenofovir alafenamide is reduced from 25 to 10 mg daily when given with boosting agents. However, such… 
2017
2017
Recent observations on intolerance of dolutegravir: differential causes and consequences.
2016
2016
Executive summary of the GESIDA/National AIDS Plan Consensus Document on Antiretroviral Therapy in Adults Infected by the Human Immunodeficiency Virus (Updated January 2016).
Review
2015
Review
2015
Darunavir/cobicistat once daily for the treatment of HIV
A current focus in HIV management is improving adherence by minimizing pill burden with convenient formulations, including fixed… 
2014
2014
Advancing the portfolio of tuberculosis diagnostics, drugs, biomarkers, and vaccines.
Review
2014
Review
2014
Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences.
Review
2014
Review
2014
The HIV pipeline
The developmental pipeline of HIV antiretroviral therapies is large and diverse, spanning a number of different drug classes… 
2014
2014
Switching From Twice-Daily Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine to Once-Daily Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed…
Abstract Background: Pill burden, dosing frequency, and concerns about safety and toler-ability are important obstacles to… 
2014
2014
Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults
COBI, a PK enhancer with no ARV activity is a more selective cytochrome P450 (CYP)3A inhibitor than ritonavir (RTV), does not… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)